RNA-based therapeutic developer DTx Pharma announced today that it completed a $100 million Series B financing round. RA Capital Management led the financing round with participation from new investors Access Biotechnology, Surveyor Capital (a Citadel company), Cormorant Asset Management, Janus Henderson Investors, and Logos Capital. Additionally, existing investors Friedman Bioventure Fund, Eli Lilly, Viva BioInnovator […]
Tandem Diabetes Care appoints Dr. Jordan Pinsker as its medical director
Tandem Diabetes Care (NSDQ:TNDM) announced today that it appointed Dr. Jordan Pinsker as its VP & medical director. The San Diego-based insulin delivery technology developer’s appointment of Pinsker will be made effective on April 26, 2021, according to a news release. Pinsker joins Tandem from Sansum Diabetes Research Institute in Santa Barbara, Calif., where he served […]
FDA approves Oncopeptides treatment for multiple myeloma
Oncopeptides (STO:ONCO) announced today that it received FDA approval for its Pepaxto treatment for multiple myeloma. Waltham, Mass.-based Oncopeptides’ Pepaxto (melphalan flufenamide) received approval in combination with dexamethasone for treating adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at […]
BriaCell Therapeutics closes $25M offering
BriaCell Therapeutics (NSDQ:BCTX) announced today that it closed an underwritten public offering worth $25 million. Berkeley, Calif.-based BriaCell offered more than 4.85 million common units comprised of one share of common stock and one warrant to purchase one share of common stock priced at $4.25 per unit, according to a news release. Additionally, the offering […]
ICU Medical dips despite Street-beating Q4
ICU Medical (NSDQ:ICUI) shares took a slight hit today on fourth-quarter results that topped the consensus forecast. The San Clemente, Calif.-based infusion therapy and critical care technology developer posted profits of $26.1 million, or $1.21 per share, on sales of $320.5 million for the three months ended Dec. 31, 2020, for a 2.7% bottom-line gain on […]
8 drug delivery innovations you need to know
The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the […]
Axonics acquires Contura and its Bulkamid bulking agent for $235M
Axonics (NSDQ: AXNX) announced today that it acquired Contura and its flagship Bulkamid product for up to $235 million. London-based Contura’s Bulkamid is a urethral bulking agent for women with stress urinary incontinence (SUI). It is a next-generation hydrogel injected into the urethral wall in a minimally invasive office or outpatient facility procedure to restore the natural closing pressure […]
Kala Pharmaceuticals slides on missed Q4 projections
Kala Pharmaceuticals (NSDQ:KALA) shares dipped this morning on fourth-quarter results that came up short of the consensus forecast. The Watertown, Mass.-based company posted losses of -$31.1 million, or -55¢ per share, on sales of $2.2 million for the three months ended Dec. 31, 2020, for a more than $10 million bottom-line slide on sales growth […]
Tandem Diabetes Care skyrockets after hours on Street-beating Q4
Tandem Diabetes Care (NSDQ:TNDM) shares soared after hours today on fourth-quarter results that topped the consensus forecast. Shares of TNDM were up 12.9% at $103.04 per share after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.8%. The San Diego-based insulin delivery and […]
Insulet rises on Street-beating Q4 revenues
Insulet (NSDQ:PODD) shares rose before the market opened today on fourth-quarter results that beat the consensus revenue forecast. The Acton, Mass.-based wearable insulin delivery system developer posted losses of -$17.1 million, or -26¢ per share, on sales of $246.1 million for the three months ended Dec. 31, 2020, for a bottom-line slide into the red on […]